Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

MLA

Massard, Christophe, et al. “Phase Ib Dose-Finding Study of Abiraterone Acetate plus Buparlisib (BKM120) or Dactolisib (BEZ235) in Patients with Castration-Resistant Prostate Cancer.” European Journal of Cancer (Oxford, England : 1990), vol. 76, May 2017, pp. 36–44. EBSCOhost, https://doi.org/10.1016/j.ejca.2017.01.024.

APA

Massard, C., Chi, K. N., Castellano, D., de Bono, J., Gravis, G., Dirix, L., Machiels, J.-P., Mita, A., Mellado, B., Turri, S., Maier, J., Csonka, D., Chakravartty, A., & Fizazi, K. (2017). Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990), 76, 36–44. https://doi.org/10.1016/j.ejca.2017.01.024

Chicago

Massard, Christophe, Kim Nguyen Chi, Daniel Castellano, Johann de Bono, Gwenaelle Gravis, Luc Dirix, Jean-Pascal Machiels, et al. 2017. “Phase Ib Dose-Finding Study of Abiraterone Acetate plus Buparlisib (BKM120) or Dactolisib (BEZ235) in Patients with Castration-Resistant Prostate Cancer.” European Journal of Cancer (Oxford, England : 1990) 76 (May): 36–44. doi:10.1016/j.ejca.2017.01.024.